



<p>1.0 Degree Title Please specify the two degrees for concurrent degree programs</p> <input type="text" value="Ph.D."/>	<p>2.0 Administering Faculty or GPS</p> <input type="text" value="Graduate and Postdoctoral Studies"/>
<p>1.1 Major (Subject/Discipline) (30-char. max.)</p> <input type="text" value="Cancer Sciences"/>	<p>Offering Faculty & Department</p> <input type="text" value="FMHS & Interdepartmental"/>
<p>1.2 Concentration (Option) (30 char. max.)</p> <input type="text"/>	<p>3.0 Effective Term of Implementation (Ex. Sept. 2019 or 201909) Term</p> <input type="text" value="202409"/>
<p>1.3 Complete Program Title (info from boxes 1.0+1.1+1.2+5.2)</p> <input type="text" value="Ph.D. in Cancer Sciences"/>	

4.0 Rationale and Admission Requirements for New Program/Concentration

Rationale: The Interdisciplinary Program in Cancer Sciences (Ph.D.) is designed to be disease- and patient-centric, reflecting the expressed desire of students for graduate training in cancer research that reflects the human component of the disease. Historically, training in the biomedical and fundamental sciences, informatics, engineering, medicine, epidemiology, and patient care occurred mainly in silos, with little opportunity for integration. This innovative program will train the next generation of leading cancer scientists across all pillars of cancer research, providing a solid foundation in fundamental aspects of cancer biology, "omics" analysis, treatment, and patient care. Admission Requirements: Applicants are required to have a Master's degree in fields related to biomedical sciences (e.g. anatomy and cell biology, biology, biochemistry, genetics, microbiology and immunology, molecular biology, pharmacology and physiology, medicine, nursing, kinesiology, physical and occupational therapy), with a minimum cumulative GPA of 3.5/4.0 on the McGill scale, as well as a B.Sc. GPA of 3.5/4.0 on the McGill scale. Exceptional candidates may be considered for direct Ph.D. entry with B.Sc. GPA of 3.7/4.0 and a strong research experience with publication record and/or highly competitive awards.

5.0 Program Information
Indicate an "x" as appropriate

<p>5.1 Program Type</p> <p>Bachelor's Program</p> <p>Master's</p> <p>M.Sc.(Applied) Program</p> <p>Dual Degree/Concurrent Program</p> <p>Certificate</p> <p>Diploma</p> <p>Graduate Certificate</p> <p>Graduate Diploma</p> <p>Professional Development Cert</p> <p><input checked="" type="checkbox"/> Ph.D. Program</p> <p>Doctorate Program (Other than Ph.D.)</p> <p>Self-Funded/Private Program</p> <p>Off-Campus Program</p> <p>Distance Education Program</p> <p>Other (Please specify)</p>	<p>5.2 Category</p> <p>Faculty Program (FP)</p> <p>Major</p> <p>Joint Major</p> <p>Major Concentration (CON)</p> <p>Minor</p> <p>Minor Concentration (CON)</p> <p>Honours (HON)</p> <p>Joint Honours Component (HC)</p> <p>Internship/Co-op</p> <p><input checked="" type="checkbox"/> Thesis (T)</p> <p>Non-Thesis (N)</p> <p>Other</p> <p>Please specify</p> <input type="text"/>	<p>5.3 Level</p> <p>Undergraduate</p> <p>Dentistry/Law/Medicine</p> <p>Continuing Studies (Non-Credit)</p> <p>Collegial</p> <p>Masters & Grad Dips & Certs</p> <p><input checked="" type="checkbox"/> Doctorate</p> <p>Post-Graduate Medicine/Dentistry</p> <p>Graduate Qualifying</p>
---	--	---

5.4 Requires Centrally-Funded Resources
Yes No

<p>6.0 Total Credits or CEUs (if latter, indicate "CEUs" in box)</p> <input type="text" value="0"/>	<p>7.0 Consultation with Related Units</p> <p>Financial Consult</p> <p>Attach list of consultations. (attached)</p>
--	--

8.0 Program Description (Maximum 150 words)

The Ph.D in Cancer Sciences program focuses on cancer as a disease and the breadth of cancer research across disciplines. This program includes a solid foundation in fundamental aspects of cancer biology, "omics" analyses, treatments, and patient care.

9.0 List of proposed new Program/Concentration

If new concentration (option) of existing program, a program layout (list of all courses) of existing program **must** be attached.

Proposed program (list courses as follows: Subj Code/Crse Num, Title, Credit Weight under the headings of: Required Courses, Complementary Courses, Elective Courses)

Ph.D. in Cancer Sciences (0 Credit)

Required Courses (4 credits)

CANC 621D1/D2 Seminars in Cancer Sciences (4 credits)
CANC 701 Ph.D. Comprehensive Exam (0 credits)



Complementary Courses (10 credits)

6 Credits from the following:

EXMD 635D1 Experimental/Clinical Oncology (3 credits)
EXMD 635D2 Experimental/Clinical Oncology (3 credits)
OR
ONCO 610D1 Fundamentals of Oncology and Cancer Research (3 credits)
ONCO 610D2 Fundamentals of Oncology and Cancer Research (3 credits)

4 credits to be taken from the following list. Students may select a 3-credit and 1-credit course or four 1-credit courses

BIOC 600 Advanced Strategies in Genetics and Genomics (3 credits)
BIOC 603 Genomics and Gene Expression (3 credits)
BIOC 605 Protein Biology and Proteomics (3 credits)
BMDE 507 Formulation and Delivery of Biotherapeutics (3 credits)
BMDE 653 Patents in Biomedical Engineering (3 credits)
BMDE 655 Biomedical Clinical Trials-Medical Devices (3 credits)
CANC 601 Patient Engagement in Cancer Research (1 credit)
CANC 602 Epidemiology in Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Cancer Caregiving; Psychosocial Issues (1 credit)
CANC 606 Tumour Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)
EPIB 507 Biostats for Health Sciences (3 credits)
EPIB 521 Regression Analysis for Health Sciences (3 credits)
EPIB 635 Clinical Trials (3 credits)
EPIB 671 Cancer Epidemiology and Prevention (3 credits)
EXMD 504 Biology of Cancer (3 credits)
EXMD 602 Techniques in Molecular Genetics (3 credits)
EXMD 607 Molecular Control of Cell Growth (3 credits)
EXMD 608 Molecular Embryology (3 credits)
EXMD 614 Environmental Carcinogenesis (3 credits)
EXMD 617 Workshop in Clinical Trials 1 (1 credit)
EXMD 618 Workshop in Clinical Trials 2 (1 credit)
EMMD 619 Workshop in Clinical Trials 3 (1 credits)
EXMD 647 Epigenetics and Cancer (3 credits)
EXSU 500 Artificial Intelligence in Medicine (3 credits)
EXSU 505 Trends in Precision Oncology (3 credits)
EXSU 606 Statistics for Surgical Research (3 credits)
HGEN 676 Lab course in Genomics (3 credits)
HGEN 677 Statistical Concepts in Genetic and Genomic Analysis (3 credits)
HGEN 679 Cancer Genetics: Precision Oncology (3 credits)
HGEN 690 Inherited Cancer Syndromes (3 credits)
HGEN 693 Using Bioinformatics Resources (3 credits)
NUR2 515 Applied Statistics for Nursing (3 credits)
NUR2 783 Psychosocial Oncology Research (3 credits)
ONCO 611 Proteomics for Precision Medicine (3 credits)
ONCO 615 Principles and Practice of Clinical Trials (3 credits)
ONCO 620 Best Practices in Biomedical Research (3 credits)
ONCO 625 Quality Improvement Principles and Methods (3 credits)
ONCO 635 Qualitative and Psychosocial Health Research (3 credits)
ONCO 645 Seminars in Global Oncology (3 credits)
PATH 652 Molecular Biology of Disease (3 credits)
PHAR 508 Drug Discovery and Development (3 credits)
PHGY 513 Translational Immunology (3 credits)
POTH 637 Cancer Rehabilitation

10.0 Approvals			
Routing Sequence	Name	Signature	Meeting Date
Department	Goodman Cancer Institute : Dr. Moraa Park		Jan 9, 2023
Curric/Acad Committee	Dr. Melissa Vollrath		Jan 23rd, 2023
Faculty 1			
Faculty 2			
Faculty 3			
CGPS			
SCTP			
APC			
Senate			
Submitted by			
Name	Rosanne Sequin	To be completed by ES:	
Phone		CIP Code	
Email	Rosanne.sequin@mcaill.ca		
Submission Date	November 21 2022		

REMINDERS:

*Box 5.4 – Must be completed; see section 6.5.4 within the New Program Guidelines at:

<https://www.mcgill.ca/sctp/guidelines>.

**All new program proposals must be accompanied by a 2-3 page support document.

Proposal for Ph.D. in Cancer Sciences Program

1. Introduction: Program Identification:

Program Title: Interdisciplinary Cancer Sciences (CANC)
Degree Title: Ph.D. (with thesis, 0 credit)
Faculty: FMHS/GPS

We propose an innovative interdepartmental and interdisciplinary Ph.D. program in Cancer Sciences, designed to train the next generation of leading cancer scientists across all pillars of cancer research. Historically, training in the biomedical and fundamental sciences, informatics, engineering, medicine, epidemiology, and patient care occurred mainly in silos, with little opportunity for integration. Now, these disciplines are rapidly evolving and converging, and it is accepted that incorporating approaches from these diverse fields of study is necessary to advance cancer research. This program will foster strong scientific and social ties among the student cohort and the wider cancer research community through interdisciplinary training and research activities, providing a solid foundation in fundamental aspects of cancer biology, “omics” analysis, treatment, and patient care. Students will gain a variety of cancer research competencies, selecting from cancer-centric interdisciplinary courses featuring active engagement and collaborative approaches. By consulting with stakeholders across the Faculty of Medicine and Health Sciences (FMHS), we have designed the program to provide students with a comprehensive understanding of cancer, including the breadth of cancer research and how integration of disciplines can advance the field.

2. Rationale for the Program

2.1. Academic significance:

Cancer is a group of complex diseases. The future of cancer care will focus on four pillars: Prevention through better understanding of the causes of cancer, improved early detection, precision medicine, and alleviating physical and psychosocial symptoms. Students from diverse fields and backgrounds will enter the program, necessitating a shared foundation in cancer sciences through cornerstone courses (EXMD635 or ONCO610) covering the cellular, molecular and genetic mechanisms of cancer, animal- and patient-derived cancer models, “-omics” approaches to studying cancer, cancer therapeutics, cancer epidemiology, cancer prevention, improving patient care and psychosocial health. The Seminars in Cancer Sciences course (CANC621) will feature faculty-guided discussions of high-impact research articles and seminars from internationally renowned scientists, initially focused on individual disciplines, but progressing to cover interdisciplinary approaches and discoveries. At the end of the second year, the students will take a qualifying exam where they will present and answer questions on their proposed thesis research as well as an interdisciplinary topic in cancer science outside their thesis research specialization, under the tutelage of a faculty mentor who is not their supervisor. The remainder of the curriculum will provide the flexibility to create individualized programs, selecting from complementary courses, including specialized 1-credit courses (each 15 hours including lectures and a hands-on or project component), beginning in the second year. This will provide time for students to gain experience and understanding of their thesis research material.

Cancer research is pursued widely across and beyond the McGill campus, making it challenging for trainees to support each other. The program’s non-credit mandatory activities will build a cohort identity among graduate students, facilitating cohesion and teamwork and fostering a feeling of unity and belonging. They will include Cohort Training Days, 3-day events in September and January each year with two days dedicated primarily to first year trainees and the third to a writing practicum open to all trainees (details in Appendix A). These events will expose trainees to all aspects of cancer through interactions with clinicians, basic and clinician-scientists, patient care professionals and patients, providing perspective on how research impacts on patients and giving the current view of the frontiers and major challenges. Another non-credit activity, the

annual Interdisciplinary Cancer Research Day, will provide opportunities for trainees to present their research to their peers and the wider cancer research community.

2.2. Strategic position of the program at McGill:

Cancer research on the McGill campus and at affiliated institutes is geographically dispersed, with major sites including the Goodman Cancer Institute (GCI), the Lady Davis Institute (LDI)/Segal Cancer Centre and the Research Institute of the McGill University Health Centre (RI-MUHC). While the Gerald Bronfman Department of Oncology offers a graduate diploma in oncology, there is currently no thesis-based MSc or PhD program specifically dedicated to cancer sciences at McGill. Instead, students enroll in departments and divisions with their own specialized training paths, including Biochemistry, Anatomy and Cell Biology, Biology, Physiology, Pathology, Pharmacology and Therapeutics, Human Genetics, Microbiology and Immunology, Biological and Biomedical Engineering, Experimental Medicine, Experimental Surgery, Epidemiology, Biostatistics, Occupational Health, and the Ingram School of Nursing. This new program will create a dedicated community of cancer research trainees from across these units, with training focused on cancer sciences, and provide opportunities to collaborate and explore common interests.

The program will align extremely well with the FMHS Education Strategic Plan (2018). Rather than focusing solely on technology, themes or mechanisms, it is designed to be disease- and patient-centric, reflecting the expressed desire of students for graduate training in cancer research that reflects the human component of the disease. The program will encourage the integration of clinical knowledge with fundamental and curiosity-driven research, fostering a flow of ideas and knowledge, with the goal of improving cancer treatment and patient care. These initiatives will contribute to realizing the FMHS strategic goals of advancing evidence-based, learner-centred approaches (*Goal 1: Teach*), including through extensive consultation with trainees. The program will also be vital to supporting the development of a collaborative, interdisciplinary and interprofessional educational environment at McGill (*Goal 2: Learn*).

2.3. Strategic position of the program within Quebec/Canada/International contexts:

In Quebec, Université Laval, Université de Sherbrooke, Université de Montréal and McGill University have thriving cancer research centers linked with their respective medical schools. However, none have a Ph.D. program in cancer science research. Examples of cancer science and cancer biology graduate programs offered in Canada, the U.S., and Europe are shown below.

University	Program/Degree (s) offered	Description
CANADA		
University of British Columbia	Interdisciplinary Oncology Program (M.Sc./ Ph.D)	2 core courses/electives specific to thesis research
Western University	Interdisciplinary Medicine (M.Sc. no thesis)	Lab rotations, clinical, basic science and community engaged learning
Queen's University	Multidisciplinary Graduate Program in Cancer Research (M.Sc. / Ph.D.)	Student research thesis is cancer focused, but not a centralized program.
University of Alberta	Cancer Sciences Specialization (M.Sc./ Ph.D.)	Not interdisciplinary Cancer biology focus
University of Calgary	Medical Sciences (M.Sc./ Ph.D.)	Not interdisciplinary Specialization in cancer biology
Memorial University of Newfoundland	Cancer Development and Research (M.Sc. / Ph.D.)	Training in cancer biology research or developmental biology
USA		
Memorial Sloan Kettering Cancer Center (NY)	Cancer Biology (Ph.D.)	Interdisciplinary cancer biology with elective clinical apprenticeship
Stanford University (CA)	Cancer Biology (Ph.D.)	Not interdisciplinary
Cold Spring Harbor (NY)	Cancer Biology (Ph.D.)	Not interdisciplinary
EUROPE		
Karolinska Institute (Sweden)	Tumor Biology and Oncology (doctorate)	Clinical and translational cancer research (starting Spring 2024)

University of Glasgow (Scotland)	Cancer Sciences (Ph.D.)	Cancer biology, translational and clinical research
German Research Center Heidelberg (DKFZ)	Interdisciplinary Program (Ph.D.)	Basic, computational, epidemiological, and translational cancer research

Given the overall paucity of thesis-based graduate programs in interdisciplinary cancer sciences, the high demand, and the growth of interdisciplinary cancer research, the proposed program will position Quebec and Canada at the forefront of training future leaders in cancer science.

2.4. Market study for the initiative:

Many students are interested in developing their understanding of the total scope of cancer research, but the breadth of interdisciplinary research can be challenging and overwhelming. The program is designed to overcome these challenges by covering different discipline foundations, supporting curiosity-driven exploration of cancer research and leveraging students' diverse research backgrounds as a source of strength, encouraging them to collaborate and share ideas. Trainees completing the program will have acquired competencies allowing them to pursue careers in academic teaching and research, policy and administration in government, healthcare, and non-profit organizations, as well as positions in the pharmaceutical and biotechnology industries. The global cancer market is expected to grow to \$500 billion by 2030, with accompanying demand for graduates with interdisciplinary training. Our program will position trainees to take advantage of these opportunities.

3. Program Overview

3.1. Structure and Admission:

Students will pursue cancer research theses in a broad range of disciplines but will come together in the fundamental (EXMD635 or ONCO610) and cornerstone (CANC621) courses. They will perform original scholarly research, write and orally defend a thesis, and complete pre-defined competencies in methodology, academic knowledge of their research fields and professional skills. Students are encouraged to continue to learn throughout their degree and will have access to complementary courses in years 2-4.

Proposed Timetable of Courses for each Year in Program:

Calendar Years (Ph.D. Yr based on students entering with Master's.)	Year 1 (Ph.D. Yr 2)	Year 2 (Ph.D. Yr 3)	Year 3 (Ph.D. Yr 4)	Year 4 (Ph.D. Yr 5)	Year 5 (Ph.D. Yr 6)
Fundamental Course: EXMD635D1/D2 or ONCO610D1/D2					
CANC621D1/D2: Seminars in Cancer Sciences					
CANC 701 Comprehensive Exam (by end Year 2)					
Complementary 3 credit course selection					
Complementary 1 credit course(s) selection					
Thesis Research					
Interdepartmental Cancer Seminars (non credit)					
Cohort Training Days (Sept and Jan) (non credit)					
Interdisciplinary Cancer Sciences Research Day (non credit)					

Admission: Applicants are required to have a Master's degree in fields related to biomedical science with a minimum cumulative GPA of 3.5/4.0 on the McGill scale. Exceptional candidates may be considered for direct Ph.D. entry with B.Sc. GPA of 3.7/4.0 and a strong research experience with publication record and/or highly competitive awards.

Application Documents:

Applicants will provide their most recent curriculum vitae, a 1000-word personal statement describing their educational and professional background, and their motivation for applying, as well as two letters of reference from individuals with whom they interacted on an academic or professional level, and all transcripts from their post-secondary education. If the applicant has identified a potential thesis supervisor, they must also include a letter from them.

Appendix A: Mandatory Academic Activities (non-credit)

1. Cohort Training Days

The Training Days will provide a structured platform to introduce basic, yet critical, skills that are important across all streams of cancer sciences. Training Days will take place twice per year, in September and January, each spread over 3 days (Monday-Wednesday). Two days will be dedicated primarily to first year trainees, while the third day will be an open *Writing Practicum* where trainees from all years are encouraged to participate.

The two Training Days will be built as combinations of 5 types of blocks:

- 1- Introductory short courses on key cancer topics: interdisciplinary scientific engagement, highlights of recent scientific advances
- 2- Research management: experimental design, planning with timelines, milestones and contingencies, ethics, basic statistics
- 3- Communication skillsets: poster presentations, scientific communication to lay audiences
- 4- Clinicians, researcher, patient and patient family testimonies.
- 5- Team building and networking: team-based problem solving, EDI, leadership skills, engagement with committees and community, career management including cv preparation

The *Writing Practicum* will cover topics including how to write:

- a research scholarship application
- a scientific abstract for congress/conference
- a scientific paper
- a thesis proposal
- a thesis

2. Interdisciplinary Cancer Sciences Research Days

Interdisciplinary Cancer Sciences Research Day (to take place in May) will be a required activity for all students enrolled in the Cancer Sciences Program. The objectives are to:

- 1- Reinforce the inter-disciplinary nature of cancer research/cancer care through presentations and group activities.
- 2- Provide an opportunity for new students to connect with and learn from students in the second year and beyond.
- 3- Provide second- and third-year students the opportunity to organize speaker sessions, and plan and lead a discussion group.
- 4- Provide an opportunity for students in the program to present their work either as a poster presentation or as a 10-minute oral presentation. *

*Students in the second year and above will submit an abstract to the Curriculum Committee. Members of the Curriculum Committee will review the abstracts and decide if the student will be invited to give an oral presentation or a poster presentation. The oral presentations should include different cancer research disciplines. The Fellowships and Awards committee members will vote on the best poster presentation and the best oral presentation.

Hosting of the Research Days will rotate annually between the Goodman Cancer Institute (GCI), the Research Institute of the McGill University Health Centre (RI-MUHC) and the Lady Davis Institute (LDI)/Segal Cancer Centre which will also support students in the programs to know the different sites involved in the program.

**McGill****Institut du cancer
Rosalind & Morris Goodman
Cancer Institute**

Morag Park, Ph.D., C.Q., FRSC, FCAHS
Rosalind and Morris Goodman Cancer Institute
Cancer Pavilion, McGill University
1160 des Pins West, Room 514
Montreal, Québec, Canada H3A 1A3
T: (514) 398-5749
F: (514) 398-6769

Institut du cancer Rosalind et Morris Goodman
Pavillon du Cancer, Université McGill
1160 des Pins Ouest, bureau 514
Montréal, Québec H3A 1A3 Canada
T : (514) 398-5749
F: (514) 398-6769

DATE: November 21, 2022

From: Dr. Morag Park, Director, Rosalind and Morris Goodman Cancer Institute

To: Working Committee for the *Interdisciplinary Ph.D. Program in Cancer Sciences*

This letter is to state that I have read, revised and fully endorse the proposal for the new *PhD Interdisciplinary Program in Cancer Sciences*.

Cancer sciences have changed significantly over the past decade and have progressively transitioned integrating interdisciplinary and patient-centric disciplines and now must encompass the full axis of biomedical, clinical and patient care disciplines.

In close collaboration with its many partners at McGill, the Rosalind and Morris Goodman Cancer Institute has engaged as a key partner in developing the vision and scope of this exciting new paradigm of training in cancer sciences. In my view, the Interdisciplinary Program in Cancer Sciences is both timely and necessary to prepare the next generation of learners supporting the broad range of learning expertise and career goals fulfilling future needs of Québec and Canadian societies.

Sincerely yours,

Morag Park, Ph.D., C.Q., FRSC, FCAHS
Director, Goodman Cancer Institute
Diane and Sal Guerrera Chair in Cancer Genetics
Distinguished James McGill Professor, Depts. of Oncology, Biochemistry and Medicine

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday November 30, 2022

**TO: Dr. Anne-Marie Lauzon
Division of Experimental Medicine
Glen Site - McGill University Health Centre
1001 Décarie Boulevard,
Montreal, Quebec, Canada, H4A 3J1**

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to courses offered by your division:

EXMD 635D1/D2 Experimental and Clinical Oncology (6 credits)
EXMD 602 Techniques in Molecular Genetics (3 credits)
EXMD 607 Control of Cell Growth (3 credits)
EXMD 608 Molecular Embryology (3 credits)
EXMD 614 Environmental Carcinogenesis (3 credits)
EXMD 634 Quantitative Research Methods (3 credits)
EXMD 647 Epigenetics and Cancer (3 credits)
EXMD 504 Biology of Cancer (3 credits)
EXMD 617 Workshop in Clinical Trials 1 (1 credit)
EXMD 618 Workshop in Clinical Trials 2 (1 credit)
EXMD 619 Workshop in Clinical Trials 3 (1 credit)

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Division of Experimental Medicine, if they so wish to attend.

CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

 X* NO OBJECTIONS _____ SOME OBJECTIONS
COMMENTS:

This is an excellent initiative that will promote cancer studies at McGill University. Experimental Medicine supports this new program.

*However, we do have some concerns with regards to some of the EXMD courses proposed as required or complementary courses for this program. Please see details on the next page.

Signature: 

Date: December 12, 2022

EXMD 635D1/D2 Experimental and Clinical Oncology. This course is listed as one of two options for the required courses for this program. Currently this course has a capacity of 30 students, and it is usually full. To set aside the requested 5-8 seats in the course, we would need to increase the capacity so as not to limit registration by ExMed students. This would therefore require the CANC program to secure additional funding to support a TA to help the course coordinator.

The following courses have been listed as “complementary courses” for this program. Setting aside 1-3 seats should not be a problem, however if the CANC program continues to grow and additional seats are requested, then this may present an issue as the courses generally fill up each year:

EXMD 602 Techniques in Molecular Genetics, capacity 16

EXMD 607 Control of Cell Growth – capacity 27

EXMD 608 Molecular Embryology – only offered every other year

EXMD 614 Environmental Carcinogenesis – capacity 14

EXMD 647 Epigenetics and Cancer, capacity 18

EXMD 617 Workshop in Clinical Trials 1, **EXMD 618** Workshop in Clinical Trials 2, and **EXMD 619** Workshop in Clinical Trials 3

We do have concerns about reserving seats in the following courses:

EXMD 504 Biology of Cancer. This course has a capacity of 85 students and is always oversubscribed. If there is significant interest from students to take this course, then we would need to increase the course capacity and have the CANC program secure funding for additional TA hours.

EXMD 634 Quantitative Research Methods. This course has a capacity of 35 students, and again is always oversubscribed. This course is currently restricted to ExMed students. At this point we are unable to set aside seats in the class for CANC students, as we often cannot accommodate our own students.

Regarding the 1-credit CANC courses, they are excellent for students who will perform cancer research. ExMed students will be permitted to take these 1-credit courses provided that they are relevant to their field of research. Moreover, we will request that they select 3 of them to substitute one of their 3-credit course requirements.

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday November 30, 2022

**To: Chair, Dr. Eduardo Franco
Gerald Bronfman Department of Oncology
5100 de Maisonneuve Blvd West
Suite 720
Montreal, Quebec H4A 3T2 Canada**

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to courses offered by your division:

**ONCO 610 D1/D2 Fundamentals of Oncology and Cancer Research (6 credits)
ONCO 611 Proteomics for Precision Medicine (3 credits)
ONCO 615 Principles and Practice of Clinical Trials (3 credits)
ONCO 620 Best Practices in Biomedical Research (3 credits)
ONCO 615 Quality and Improvement Principles and Methods (3 credits)
ONCO 635 Qualitative and Psychosocial Health Research (3 credits)
ONCO 645 Seminars in Global Oncology (3 credits)**

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Gerald Bronfman Department of Oncology, if they so wish to attend.

**CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)**

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

 X **NO OBJECTIONS** **SOME OBJECTIONS**

COMMENTS: I am very enthusiastic about this initiative

Signature:



Date: December 12, 2022

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday November 30, 2022

To: Chair, Dr. Albert Berghuis
Department of Biochemistry
McIntyre Medical Building
3655 Promenade Sir-William-Osler
Room 905
Montréal, Québec H3G 1Y6 Canada

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to courses offered by your division:

BIOC 600 Advanced Strategies in Genetics and Genomic (3 credits)
BIOC 603 Genomics and Gene Expression (3 credits)
BIOC 605 Protein Biology and Proteomics (3 credits)

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Department of Biochemistry, if they so wish to attend.

CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

 X NO OBJECTIONS SOME OBJECTIONS

COMMENTS:

- We find the structure of the program innovative in that it offers students a lot of flexibility.
- The program could also offer a 1 credit tutorial on personalized cancer treatment.
- Consider opening an option to complete a PhD in more than one lab as an attractive multi-disciplinary advantage to the program.
- Linking the new program with the McGill MD-PhD program may be beneficial.

Signature: Bhudson Nagan

Date: December 12, 2022

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday November 30, 2022

To: Department of Biomedical Engineering
Department Chair: David Juncker
Duff Medical Building
Room 316
3775 rue University
Montréal, Québec H3A 2B4 Canada

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to courses offered by your division:

BMDE 501 Selected Topics: Biomedical Engineering (3 credits)
BMDE 507 Formulation and Delivery of Biotherapeutics (3 credits)
BMDE 653 Patents in Biomedical Engineering (3 credits)
BMDE 655 Biomedical Clinical Trials: Medical Devices (3 credits)

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Department of Biomedical Engineering, if they so wish to attend.

CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

 X **NO OBJECTIONS** **SOME OBJECTIONS**

COMMENTS:

This is an interesting program proposal, and we are happy to see that its prospective students might also take courses from our program. Students are welcome to register in BMDE 653 and BMDE 655 as space allows, but the pertinence of BMDE 653 to this program may need some further consideration.

Finally, we recognize that nearly all departments have graduate students working on oncology related research, but it is unclear if this joint program takes away graduate students from our Department, or whether this a joint program with external departments. If the latter, it would be helpful to clarify the administrative arrangement.

Signature:

Devon MA

Date:

February 8, 2023

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday November 30, 2022

**To: Department of Epidemiology, Biostatistics and Occupational Health
Department Chair: Josée Dupuis
2001 McGill College, Suite 1200
Montréal, Québec H3A 1G1 Canada**

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to courses offered by your division:

EPIB 507 Biostats for Health Sciences (3 credits)
EPIB 521 Regression Analysis for Health Sciences (3 credits)
EPIB 635 Epidemiology and Biostatistics (3 credits)
EPIB 671 Cancer Epidemiology and Prevention (3 credits)

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Department of Epidemiology, Biostatistics and Occupational Health, if they so wish to attend.

CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

_____ **x** _____ **NO OBJECTIONS** _____ **SOME OBJECTIONS**

COMMENTS:

I have checked with the instructors for the EPIB courses listed above, and all instructors agreed that they could accommodate 1-3 students/year from this new program. The EPIB 635 instructor had the following comment: *“I'd be happy to have students from this program enroll in EPIB 635. However, I should mention that the course description on the eCalendar is old and inaccurate: this course was developed in 2020 and is focused on statistical aspects of clinical trials. It covers statistical methodology relevant to oncology trials including adaptive and flexible designs, information borrowing, etc. But these methods require a solid statistical background including Bayesian statistics which is not normally included in intro stat courses.”*

Signature:

Date:



December 6, 2022

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday November 30, 2022

**TO: Department of Human Genetics
Department Chair: Eric Shoubridge
Rm 2/38, Strathcona Anatomy & Dentistry Building
Montréal, Québec H3A 0C7 Canada**

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to courses offered by your division:

HGEN 676 Lab Course in Genomics (3 credits)
HGEN 677 Statistical Concepts in Genetic and Genomic Analysis (3 credits)
HGEN 679 Cancer Genetics: Precision Oncology (3 credits)
HGEN 690 Inherited Cancer Syndromes (3 credits)
HGEN 693 Using Bioinformatic Resources (3 credits)

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Department of Human Genetics if they so wish to attend.

CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

_____ **x** _____ **NO OBJECTIONS** _____ **SOME OBJECTIONS**

COMMENTS: I assume that students in this program will be registered in one or the other departments in FOM, but will opt for a specialization in cancer? I am curious as to why you restrict the program to doctoral students, as many MSc students fast track into the PhD, and the proposed program does not offer this possibility. I am curious about what is meant by the following sentence in the executive summary “Achievement of core competencies will be evaluated robustly using a structuring competency ladder in cancer sciences”. Looks like you are proposing another level of evaluation, but it not at all clear to me what this means in practice.

I have no objections to opening the courses in HGEN to students in the program, but it is not possible to allot slots. The lab course in Genomics has very limited enrollment and it is unlikely that students in the Cancer program would be admitted unless they are registered in the HGEN graduate program. The one credit courses sound like a reasonable idea, and I like the fact that they are really

targeted to specific audiences. I guess pass/fail is appropriate here, though some students may prefer a grade.

Signature:

A handwritten signature in blue ink that reads "Eric A. Shurbridge". The signature is written in a cursive style with a light blue background behind it.

Date:

5 December, 2022

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday November 30, 2022

**TO: Department of Human Genetics
Department Chair: Eric Shoubridge
Rm 2/38, Strathcona Anatomy & Dentistry Building
Montréal, Québec H3A 0C7 Canada**

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to courses offered by your division:

HGEN 676 Lab Course in Genomics (3 credits)
HGEN 677 Statistical Concepts in Genetic and Genomic Analysis (3 credits)
HGEN 679 Cancer Genetics: Precision Oncology (3 credits)
HGEN 690 Inherited Cancer Syndromes (3 credits)
HGEN 693 Using Bioinformatic Resources (3 credits)

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Department of Human Genetics if they so wish to attend.

CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

X

_____ **NO OBJECTIONS** _____

_____ **SOME OBJECTIONS** _____

COMMENTS:

HGEN677 is currently capped at a max of 25 students. Most years, there are almost this number of students enrolled. It would certainly be possible to have a few more students in the course. Depending on numbers, a slightly larger classroom would be needed, and possibly a few more hours of TA time.

Signature:

Celia Greenwood

Date:

4 December 2022 _____

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday November 30, 2022

**TO: Department of Human Genetics
Department Chair: Eric Shoubridge
Rm 2/38, Strathcona Anatomy & Dentistry Building
Montréal, Québec H3A 0C7 Canada**

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to courses offered by your division:

**HGEN 676 Lab Course in Genomics (3 credits)
HGEN 677 Statistical Concepts in Genetic and Genomic Analysis (3 credits)
HGEN 679 Cancer Genetics: Precision Oncology (3 credits)
HGEN 690 Inherited Cancer Syndromes (3 credits)
HGEN 693 Using Bioinformatic Resources (3 credits)**

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Department of Human Genetics if they so wish to attend.

**CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)**

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

X NO OBJECTIONS _____ SOME OBJECTIONS

COMMENTS:

1. HGEN 676 Lab Course in Genomics (3 credits)

This course, offered annually, is often oversubscribed. Priority will be given to graduate students earning their degrees in the Department of Human Genetics.

2. HGEN 677 Statistical Concepts in Genetic and Genomic Analysis (3 credits)

This course, offered in alternative years, is often oversubscribed. Priority will be given to graduate students earning their degrees in the Department of Human Genetics.

3. HGEN 679 Cancer Genetics: Precision Oncology (3 credits)

This course is offered annually. Priority will be given to graduate students earning their degrees in the Department of Human Genetics.

4. HGEN 690 Inherited Cancer Syndromes (3 credits)

This course is being considered for revision and is not currently offered.

5. HGEN 693 Using Bioinformatic Resources (3 credits)

This course, offered in alternative years, is often oversubscribed. Priority will be given to graduate students earning their degrees in the Department of Human Genetics.

Further comments were addressed in direct communication.

On behalf of Eric Shoubridge, Chair, Department of Human:

Patricia N. Tonin, PhD

Professor

Chair, Science Curriculum Committee

Department of Human Genetics

Signature:



Date:

January 18, 2023

Re: New Interdisciplinary PhD Program in Cancer Sciences - request for consultation



 You replied on Mon 2022-12-12 12:57 PM



Josee Bonneau, Prof.

To: Rosanne Marie Seguin, Dr



Mon 2022-12-12 12:52 PM

Hello Dr. Seguin,

Thank you for reaching out to the Ingram School of Nursing.

I apologize for the delay as I was seeking input from our graduate Program Directors.

We would be more than happy to include your students in both NUR2 515 and NUR2 783. We would not require any resources given the small number of students this would represent.

Regarding your course outlines, we feel they are well developed and complete. We do not have any suggestions to make.

Please do not hesitate to reach out should you have any additional questions.

Very best,
Josee

Josée Bonneau

Associate Director – Education, Assistant Professor / Directrice Adjointe – Éducation, Professeure adjointe
Ingram School of Nursing / École des sciences infirmières Ingram

McGill University / Université McGill

680 Sherbrooke Ouest, 19e étage, bureau 1931
Montréal (Québec) H3A 2M7
T 514-398-4149

www.mcgill.ca/nursing

[Facebook](#) | [Twitter](#) | [Instagram](#)

Working hours: *Monday, Tuesday, Wednesday, Thursday & Friday (9:00am-5:00pm)*

Heures de travail: *Lundi, mardi, mercredi, jeudi et vendredi (9h à 17h)*

This e-mail contains information that may be confidential or privileged. If you have received this e-mail in error, please notify the sender immediately.

Ce courriel contient des renseignements qui peuvent être confidentiels. Si vous avez reçu ce courriel par erreur, veuillez en aviser immédiatement l'expéditeur.

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday November 30, 2022

TO: Department of Pathology
Department Chair: (Interim) Dr. Marie-Christine Guiot
Duff Medical Building (B Wing)
3775 University Street, Room B4
Montréal, Québec H3A 2B4 Canada

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to course offered by your division:

PATH 652 Molecular Biology of Disease (3 credits)

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Department of Pathology if they so wish to attend.

CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)


Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

NO OBJECTIONS

COMMENTS:

Cancer is treated by multidisciplinary teams in the clinical world, based on data from multiple sources clinical, imaging, pathology, genomics, genetics....
An interdisciplinary program in Cancer Sciences is a great initiative.

Signature:



Date:

December 11th 2022

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday December 1, 2022

**TO: Department of Pathology
Graduate Program Director: Dr. Edith Zorychta
Duff Medical Building (B Wing)
3775 University Street, Room B4
Montréal, Québec H3A 2B4 Canada**

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to course offered by your division:

PATH 652 Molecular Biology of Disease (3 credits)

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Department of Pathology if they so wish to attend.

**CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)**

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

_____ none NO OBJECTIONS _____ SOME OBJECTIONS

COMMENTS: COURSES: The 1-credit courses are a good idea – they focus on a specific topic and cover it in a few days, so they are easy to fit into a research schedule. The topics are well chosen and each course is directed to a subset of students who require information and sometimes practical training in a certain area. The course on mouse models is particularly impressive and will be a great help for students who are beginning research projects using these animals.

PROGRAM: The proposed Interdisciplinary PhD Program in Cancer Sciences will be a welcome addition to our many excellent graduate training programs that currently are centered within specific departments.

FUNDING: Adding a few more students to our PATH 652 course would not increase the cost. However, adding additional graduate students within the Faculty will require more resources to support them – the current FMHS minimum for a Canadian PhD student is \$25K; it is \$40K for an international student, and this is expected to rise significantly each year. A campaign to raise money for scholarships/bursaries for the program would be very beneficial.



Signature: _____
December 1, 2022

Date: _____

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday November 30, 2022

**To: Department of Pharmacology and Therapeutics
Department Chair: Dr. Koren Mann
McIntyre Medical Building
3655 Promenade Sir-William-Osler
Room 1325
Montréal, Québec H3A 1G1 Canada**

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to course offered by your division:

PHAR 508 Drug Discovery and Development (3 credits)

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Department of Pharmacology and Therapeutics if they so wish to attend.

**CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Bioinformatic Tools in Cancer Research (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)**

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

_____ **NO OBJECTIONS** _____ **SOME OBJECTIONS**

COMMENTS:

PHAR 508: I believe Dr. Hebert has also been consulted and I agree with him that a small number of students can probably be accommodated. However, if the number is increased, a discussion will need to be initiated regarding contribution towards TA stipends. In addition, there are several pre-requisites for this course. If the student has not taken these at McGill, permission of the instructor will need to be acquired. Finally, this is an undergraduate course, and this should be recognized by the PhD students enrolling.

General Comments: I applaud the idea of developing a cancer program that encompasses across all pillars of investigation. This is and will continue to grow in importance in training of the future cancer researchers. However, it is unclear where the intersection of the two groups (basic vs clinical) will occur. As I see the content, this will only occur through the required seminar course and the bi-yearly workshops. As written, there is no single foundational course. Thus, I worry that a “cohort” identity will not be established. There may be another problem for those students recruited from McGill; they may have already taken ONCO 610

or EXMD 635. A plan should be developed for this case, especially if using the ONCO certificate as a recruitment population. Finally, I think that those students not engaged in basic research will require both a qualitative and quantitative methods course in order to successfully complete their research. This is not acknowledged, nor does it fit within the 4 complimentary course credits.

Signature: *Karen Man*

Date: **December 5, 2022**

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Monday November 30, 2022

**To: Department of Pharmacology and Therapeutics
Department Chair: Dr. Koren Mann
McIntyre Medical Building
3655 Promenade Sir-William-Osler
Room 1325
Montréal, Québec H3A 1G1 Canada**

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to course offered by your division:

PHAR 508 Drug Discovery and Development (3 credits)

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Department of Pharmacology and Therapeutics if they so wish to attend.

**CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Bioinformatic Tools in Cancer Research (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)**

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

These courses seem well-designed in general. I wonder why you cannot accept students that fast track to PhD programs without obtaining their MSc degrees?

_____ **NO OBJECTIONS** **X** **SOME OBJECTIONS**

COMMENTS: I know you've stated 1-3 students could be added to our PHAR 508 course. That seems reasonable. But if you could contribute to ½ TA position if this number increases that would make it entirely possible.

Signature:

A handwritten signature in purple ink, appearing to read "Terry West".

Date:

December 3, 2022_____

**CONSULTATION REPORT FORM
RE PROGRAM and COURSE PROPOSALS**

DATE: Thursday November 30, 2022

**To: Department of Physiology
Department Chair: John White
3655 Promenade Sir William Osler
Montréal, Québec H3G 1Y6 Canada**

FROM: The Working Committee for the Interdisciplinary Ph.D. Program in Cancer Sciences

The attached proposal has been submitted to the Curriculum/Academic Committee, and it has been decided that your department should be consulted.

We are requesting students in the proposed program to have access to course offered by your division:

PHGY 513 Translational Immunology (3 credits)

We also would like your feedback regarding our proposed 1-credit courses which will be open to students from Department of Physiology if they so wish to attend.

**CANC 601 Patient Engagement in Cancer Clinical Studies and Research
CANC 602 Epidemiology of Cancer (1 credit)
CANC 603 Mouse Models in Cancer (1 credit)
CANC 604 Cancer Genomics Data Analyses (1 credit)
CANC 605 Psychosocial Issues of Cancer Patients and Caregivers (1 credit)
CANC 606 Tumor Microenvironment (1 credit)
CANC 607 Cancer Immunotherapies (1 credit)
CANC 608 Oncometabolism (1 credit)**

Would you be good enough to review this proposal and let me know before December 12, 2022, on this form, whether your department has any objections to, or comments regarding, the proposal.

x _____ NO OBJECTIONS _____ SOME OBJECTIONS

COMMENTS: Excellent program. I like the 1-credit workshop-style courses.

Signature:  _____

Date: Nov. 30, 2022

